Biotech Values

[urche]

Re: DNDN

If Provenge is safe and extends survival, as an investor I don’t care all that much how good a target it targets.

I agree with you to the extent that a survival advantage with a PAP based vaccine is of prime importance now. But,you would care a great deal if Provenge became obsolete within a year or two after launch because it was replaced by a better, more specific and more effective vaccine---in effect the target that we should have been working on and investing in all along.